Plastoquinone decyl triphenylphosphonium bromide is under clinical development by Mitotech and currently in the Phase I, Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Plastoquinone decyl triphenylphosphonium bromide’s likelihood of approval (LoA) and phase transition for Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) took place on 24 Nov 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Plastoquinone decyl triphenylphosphonium bromide Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Plastoquinone decyl triphenylphosphonium bromide overview

Visomitin (SkQ1 eye drops) is under development for the treatment of dry eye, uveitis, Leber’s hereditary optic neuropathy, dry macular degeneration and glaucoma. It is synthesized on the basis of plastoquinone (an antioxidant from plant chloroplasts). The drug candidate is formulated as a drops-solution for the ophthalmic route of administration. It was also under development for the treatment of wet AMD.

Mitotech overview

Mitotech a subsidiary of Mitotech LLC, develops antioxidant molecules targeting mitochondria. The company develops products using its lead compound SkQ1, a highly efficient mitochondria-targeted antioxidant, which is being developed for several drug formulations and methods of administration. Its pipeline portfolio consists of Visomitin, SkQ1 eye drops, which are in Phase II and Phase III trials for the treatment of uveitis and dry eyes, respectively and Plastomitin, SkQ1 pills. The company develops products for various therapeutic areas such as age-related disorders neurodegenerative, cardiovascular, ophthalmic and metabolic disorders. Mitotech is headquartered in Vallee, Luxembourg.

Quick View Plastoquinone decyl triphenylphosphonium bromide LOA Data

Report Segments
  • Innovator
Drug Name
  • Plastoquinone decyl triphenylphosphonium bromide
Administration Pathway
  • Ophthalmic
Therapeutic Areas
  • Ophthalmology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.